Peter Grayson

I’m out of here. Will find different platforms to share research results. ✌️

@SgRheumer @ACRheum I think your pic from the Takayasu’s session was a little early! The session was completely full for the talks - which is a big deal for a rare disease that certainly needs more attention!

#FOMO When everyone is attending the @ACRheum #lupus guideline update next door but you really have to attend the session on #Takayasu #arteritis #ACR24 #ACR2024

@Amansharmapgi @TerrierBen @philseo @dpgi_chandigarh @IJRheum @IndianRheum @DurgaPrasannaM1 @dada2foundation @maferradastrong @shimonakTOI What a legend! Great to see you!

#ACR2024. Presented our data on 101 DADA2 patients from India. Mesenteric ischemia, stroke and non usage of Anti TNFs was associated with mortality. attended vasculitis investigators meeting, met friends, a memorable trip.

@EBRheum @RheumNow Didn’t they allow patients with a prior history of TCZ to be included but specifically excluded those patients who were previously treatment refractory to TCZ?

Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695

@emmamgroarke @NIH I love that #149

The @NIH deer are out and about 😊🦌

@drdavidliew @VasculitisUMCG @RheumNow Lots of data converging to this observation. Only scary if it impacts longterm outcomes. Treat to target with imaging based outcomes has not proven to be wise across a spectrum of rheum diseases. Maybe future drugs will eliminate vascular inflammation. Maybe won’t matter.

Does TCZ switch off GCA histopathologically? GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery biopsy (contralat) Despite serological remission on TCZ, a heap had active histopath findings & PET still active. Scary #EULAR2024 OP0233 Reggio Emilia @RheumNow

News: Skin manifestations in VEXAS syndrome are common and provide an important early clue to the diagnosis of this life-threatening disease. Read the full NIAMS-led study via @JAMADerm 🔒. Abstract: jamanetwork.com/journals/jamad…

A look back at the first workshop on #VEXAS syndrome! > 100 participants from 19 countries came in Paris. Thanks to the support of @contactfai2r. @TerrierBen @mekinian2 @petercgrayson @maferradastrong @KosmiderO @_ERNRITA @RimBourguiba1 @CiprianJurcut

Many thanks to our French colleagues for hosting the first international VEXAS Congress in Paris. The only thing that was better than the science was the friendship. We had the best time with you! @SophieGeorgin @TerrierBen @mekinian2 @bhavishap29 @emmamgroarke @maferradastrong

@tcboyle A haiku in every bottle

The sake retreats. I absorb everything. One day I will die.

@GrantSchulert Two kinds of grown ups: those who hate Disney and those who love it. Choose love!

And we are off #disneymagic

UBA1 somatic mutations of indeterminate potential? our provocative finding in @AllofUsResearch led by @rheumrob with @jamesfbrogan, @kwbyram & @petercgrayson @VUMC_MedPSTP, @VUMCRheum @NIH_NIAMS

Population databases have shown very different findings related to VEXAS, reflecting selection bias. In AllofUs, 74 people with VEXAS mutations, 62 of them were female, 100% were p.Met41Leu, unclear if they have any disease phenotype. Terrific work led by @rheumrob !!!

@MCMarquesMD @DrPowerHays Tasha Morrison calls me Steve so I am pretty much good with whatever you want to do! As long as it’s not Dr Grayson!

@petercgrayson @DrPowerHays If you want to, I will =)

Leaving work for the last time as a fellow! Borrowing the phrase from @DrPowerHays: forever a learner, no longer a trainee! 😄 I’m forever grateful for all the amazing experiences I’ve lived in fellowship at Children’s National, at NIH and at UPMC.

@BharatKumarMD @LauraLewMad11 @EcemSevimMD @ACRheum We’ve been discussing this quite a bit lately. We just need a solid name 🤔

@LauraLewMad11 @petercgrayson @EcemSevimMD Sounds like a formidable team for @ACRheum Knowledge Bowl next year!

Annual NIAMS Medical Jeopardy hosted by @LauraLewMad11 💫 with so much knowledge and fun 🤓 Rumor has it that @petercgrayson is competing to be the host next year 🫣

Looks like CH is more a marker of inflammaging that primary driver of vasculitis - but may modify disease course

We looked at CH prevalence in three forms of vasculitis that span the age spectrum. Found that: 1. Age stronger driver of CH than vasculitis 2. Mostly small clones in DNMT3A and TET2 3. Association of clone size and relapse in GCA (unclear direction of association)

Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu’s arteritis, ANCA-associated vasculitis and giant cell arteritis ard.bmj.com/content/early/… New collaborative work from rheum and heme at NIH @fergutierrezro1 @bhavishap29 @KQuinnRheum @NealSYoung1